Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Payables (2022 - 2025)

Historic Payables for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Century Therapeutics' Payables rose 73.13% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 73.13%. This contributed to the annual value of $3.1 million for FY2024, which is 1218.53% up from last year.
  • Per Century Therapeutics' latest filing, its Payables stood at $2.6 million for Q3 2025, which was up 73.13% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Payables ranged from a high of $9.9 million in Q1 2022 and a low of $2.6 million during Q3 2024
  • Moreover, its 4-year median value for Payables was $3.5 million (2023), whereas its average is $4.2 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 6487.42% in 2023, then skyrocketed by 1218.53% in 2024.
  • Century Therapeutics' Payables (Quarter) stood at $5.5 million in 2022, then plummeted by 49.74% to $2.7 million in 2023, then grew by 12.19% to $3.1 million in 2024, then decreased by 14.89% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $3.2 million for Q2 2025, and $3.6 million during Q1 2025.